US Patent Issued to Blueprint Medicines on March 18 for "Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f[1,2,4triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis" (Massachusetts Inventors)

ALEXANDRIA, Va., March 19 -- United States Patent no. 12,252,494, issued on March 18, was assigned to Blueprint Medicines Corp. (Cambridge, Mass.).

"Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f[1,2,4triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis" was invented by Brenton Mar (Cambridge, Mass.), Anthony L. Boral (Cambridge, Mass.), Hui-Min Lin (Cambridge, Mass.) and Hongliang Shi (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Crystalline Forms of Compound (I):pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising ...